Sanjay Kalra, Abdul Hamid Zargar, G R Sridhar, Ashok Kumar Das, Jamal Ahmed, Jagdish Chander Mohan, G Vijayakumar, Ajay Kumar, Rakesh Kumar Sahay, Vageesh Ayer, Kaushik Pandit, Ganapathi Bantwal, Arun Srinivas, A G Unnikrishnan, Sushil Jindal, Saumitra Ray, Manash P Baruah, Kajal Ganguly, Sachin Mittal, Ameya Joshi, Joe George, Ganesh Hk, Nitin Kapoor, Santosh Ramakrishnan, Chetan Shah, Atul Dhingra, Balram Sharma
{"title":"Expert eValuation of Efficacy and Rationality of Vildagliptin \"EVER-Vilda\": An Indian Perspective.","authors":"Sanjay Kalra, Abdul Hamid Zargar, G R Sridhar, Ashok Kumar Das, Jamal Ahmed, Jagdish Chander Mohan, G Vijayakumar, Ajay Kumar, Rakesh Kumar Sahay, Vageesh Ayer, Kaushik Pandit, Ganapathi Bantwal, Arun Srinivas, A G Unnikrishnan, Sushil Jindal, Saumitra Ray, Manash P Baruah, Kajal Ganguly, Sachin Mittal, Ameya Joshi, Joe George, Ganesh Hk, Nitin Kapoor, Santosh Ramakrishnan, Chetan Shah, Atul Dhingra, Balram Sharma","doi":"10.1177/11795514231203911","DOIUrl":null,"url":null,"abstract":"<p><p>Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy.</p>","PeriodicalId":44715,"journal":{"name":"Clinical Medicine Insights-Endocrinology and Diabetes","volume":"17 ","pages":"11795514231203911"},"PeriodicalIF":2.7000,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10893842/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights-Endocrinology and Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795514231203911","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
